High priority for hepatitis C screening in safety net hospitals: Results from a prospective cohort of 4582 hospitalized baby boomers

Barbara J. Turner, Barbara S. Taylor, Joshua Hanson, Yuanyuan Liang, Poornachand Veerapaneni, Roberto Villarreal, Mary Perez, Ludivina Hernandez, Jasdeep Sandhu, Kristin Fiebelkorn – 6 August 2015 – Low‐income populations are disproportionately affected by hepatitis C virus (HCV) infection. Thus, implementing baby boomer screening (born 1945‐1965) for HCV may be a high priority for safety net hospitals.

Prevalence of chronic hepatitis B virus (HBV) infection in U.S. households: National Health and Nutrition Examination Survey (NHANES), 1988‐2012

Henry Roberts, Deanna Kruszon‐Moran, Kathleen N. Ly, Elizabeth Hughes, Kashif Iqbal, Ruth B. Jiles, Scott D. Holmberg – 6 August 2015 – The number of persons with chronic hepatitis B virus (HBV) infection in the United States is affected by diminishing numbers of young persons who are susceptible because of universal infant vaccination since 1991, offset by numbers of HBV‐infected persons migrating to the United States from endemic countries.

Flunarizine prevents hepatitis C virus membrane fusion in a genotype‐dependent manner by targeting the potential fusion peptide within E1

Paula M. Perin, Sibylle Haid, Richard J.P. Brown, Juliane Doerrbecker, Kai Schulze, Carsten Zeilinger, Markus von Schaewen, Brigitte Heller, Koen Vercauteren, Eva Luxenburger, Yasmine M. Baktash, Florian W.R. Vondran, Sietkse Speerstra, Abdullah Awadh, Furkat Mukhtarov, Luis M. Schang, Andreas Kirschning, Rolf Müller, Carlos A. Guzman, Lars Kaderali, Glenn Randall, Philip Meuleman, Alexander Ploss, Thomas Pietschmann – 6 August 2015 – To explore mechanisms of hepatitis C viral (HCV) replication we screened a compound library including licensed drugs.

Validation of hepatitis B virus–related hepatocellular carcinoma prediction models in the era of antiviral therapy

Kyu Sik Jung, Seung Up Kim, Kijun Song, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Kwang‐Hyub Han – 6 August 2015 – Several risk prediction models have been created to predict hepatitis B virus (HBV)‐related hepatocellular carcinoma (HCC) occurrence, with promising results. However, their prognostic performances need to be validated in the era of antiviral therapy. From 2006 to 2011, patients with chronic HBV infection were recruited and those with a history of HCC or hepatic decompensation were excluded.

Subscribe to